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measles-vaccine-associated cases. Only
three of the 11 proved abnormal (dead,'
or with neurological, educational, or
behavioural dysfunction), for whom
there were seven matched controls
defined äs before (RR 0-84; 95% CI
0-20-3-49). Although the number of
vaccine-associated cases is small, these
Undings provide no evidence of a risk of
long-term neurological damage
associated with measles vaccine.
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Third-generation oral
contraceptives and venous
thrombosis
SIR—Farmer and colleagues' show
again that third-generation
contraceptives have a higher risk of
venous thrombosis (VTE) (a significant
relative risk of 1-7), in a non-research
database without any attempt at
objective diagnosis. Since clinical
diagnoses of VTE are wrong more than
half the time,2 this will very strongly
dilute the Undings. Whether Farmer's
report deals with first thrombotic
episodes is debatable. The main
message is that the data are very
resistant: only in sub-subgroup
analyses or in an over-adjusted logistic
model, does the relative risk (almost)
disappear.
When the hypothesis of confounding
by prescribing is proposed, the analysis
should focus on risk factors for venous
thrombosis that are present at the time
of prescription in healthy young
women: age, body mass index, and
familial occurrence. Age was adjusted
in 5-year age groups in the cohort
analysis; a true demonstration of the
importance of age adjustment would be
to show that adjustment by single year
of age on the same data would make
the association disappear—that
demonstration is not reported,
however. In fact, the adjusted rate ratio
(1-7) is the same äs the crude ratio
(1-6). No Information is presented on
familial history. By contrast,
unnecessary variables were entered in
the model; some that are certain to be
correlated with oral-contraceptive
exposure, such äs months of use, and
others that will render the model
unstable because~they apply only to a
few persons, such äs "previous use of
Schering PC4", or because they are
correlated with the type of
contraceptive, such äs "recent change
of puls".
The finding of the highest relative
risk in users of a 20 μg ethinyloestradiol
third-generation pill can make perfect
sense: it is a combination of a Starter
effect and a third-generation effect.
During the period of the study the 20
μg ethinyloestradiol preparation was
predominantly prescribed to new users,
and had not been in use for long. WHO
data have shown that in the first year of
use, new users have the highest relative
risks.3 If they use a third-generation
contraceptive fheir risk doubles again.
That the increased risk of third-
generation contraceptives remains,
even with a low dose of oestrogens,
should not come äs a surprise: even the
very low doses of oestrogens äs are used
in hormonal replacement therapy have
almost the same relative risk of venous
thrombosis äs oral contraceptives.' If
such a low dose of oestrogens is
coupled to a third-generation
progestagen that further increases its
thrombogenic potential, and if this is
preferentially prescribed to new users,
we would expect the effect found by
Farmer and co-workers.
Farmer and colleagues' report
contains two gross misreadings of our
previous publication. They imply that
no previous studies applied sufficiently
fine age-stratification, and that we did
not make the distinction between 20
and 30 μg ethinyloestradiol
preparations. In the Leiden study we
adjusted by single year of age, which is
äs adequate äs age-matching with a
variable case/control ratio, and äs stated
explicitely in the text and in the table,
there were no users of 20 μg
ethinyloestradiol preparations.
Nevertheless, the same two-fold
increase in risk was found.
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SIR—It is fundamental and indeed
should be self-evident that in an
observational drug safety study the
people with the illness of interest (ie,
the cases) must, in fact, have had the
illness under study. In addition, to
invoke a possible causal connection to
the drug, individuals included äs cases
should have no other demonstrable
proximate cause of the study illness—ie,
they should reflect idiopathic disease.
These principles are especially relevant
when venous thromboembolism (VTE)
is the outcome illness since (1) a firm
diagnosis of VTE is uncertain in the
absence of diagnostic tests for
confirmation, and (2) there are many
non-drug causes of VTE, such äs
trauma, recent surgery. Unless one
examines clinical records, it is impos-
sible to ascertain whether a case of VTE
has been documented by diagnostic
tests (ie, whether it is in fact a case), nor
is it possible to establish with
confidence whether it is idiopathic.
Farmer and colleagues" study relies
solely on a general-practice, computer-
recorded diagnosis of VTE together
with a notation of anticoagulant therapy
to define the cases. Such case inclusion
is unsatisfactory since it surely includes
cases (misdiagnosed) that in fact are not
cases, äs well äs cases with a proximate
cause such äs trauma in which no drug
effect can be reasonably expected.
Computer review is inadequate to
identify such individuals.
We have published the results of
several studies relating oral
contraceptives to idiopathic VTE.2·3 In
all, whether interview based or
Computer based, we have excluded for
reasons noted above more than 50% of
potential cases from the final case series
after review of the clinical records. In
view of the failure to document and
include only relevant cases, we deem
the Information provided by Farmer
and colleagues to be uninterpretable.
Farmer and colleagues invoke strong
residual confounding by age to explain
the fmdings of our study' and others
recently reported." Their reference to
the age adjustment in our study was
incomplete and misleading. In fact,
controls were matched to cases within 2
years in 85% of instances and the mean
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